Dr. François Nader
Appointment to the Board
April 2022, previously Chair of BenevolentAI Ltd, appointed July 2021.
Experience and expertise
Dr. Nader was CEO of NPS Pharma. During his tenure, he transformed NPS Pharma into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases. He won the Ernst and Young National Life Science Entrepreneur of the Year® award in 2013 and was awarded the Ellis Island Medal of Honor® in 2017.
Before NPS, François was a venture partner at Care Capital, LLC. Prior, he served on the North America Leadership Team of Aventis Pharma and its predecessor companies holding several executive positions including Senior Vice-President, US integrated healthcare markets and North America medical and regulatory affairs. Previously, he led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc.
François is past chair of BioNJ, Acceleron Pharma and Prevail Therapeutics. He served on the board of BIO, Baxalta NPS Pharma, Alexion, Clementia Pharmaceuticals, Advanced Accelerator Applications and Noven.
François earned his French doctorate in medicine from St. Joseph University in Lebanon and a physician executive MBA from the University of Tennessee.
Current external appointments
François currently serves as chair of Talaris Therapeutics and Neurvati Neurosciences. He serves as board director of Moderna and RING Therapeutics and as senior advisor to Blackstone Life Sciences.